• 13 JUN 17

    LAGUNA HILLS, Calif., June 13, 2017 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its Chief Executive Officer, Kenneth L. Waggoner, will present PharmaCyte’s therapy for pancreatic cancer at the 2017 BIO International Convention (BIO). BIO is to be held June 17-22, 2017 in San Diego, California at the San Diego Convention Center. This year’s theme is “Breakthrough,” which is designed to highlight the breakthrough leadership, technology and science that happens every day in the biotechnology industry.

    PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commented, “We are again excited to attend this year’s BIO after just completing a working session with leading clinical oncologists at the ASCO annual meeting where we updated them on efforts to begin our clinical trial in locally advanced pancreatic cancer (LAPC).

    “Having won the 2017 Buzz of BIO ‘Pipelines of Promise’ award, we have been given the opportunity to build upon that by presenting PharmaCyte’s therapy for pancreatic cancer to thousands of industry leaders who will attend this year’s convention.

    “We are also being interviewed by Mike Huckman, a former pharmaceuticals reporter for CNBC, to showcase our pancreatic cancer therapy. And we have meetings scheduled with potential strategic partners, biotech companies that have expressed an interest in PharmaCyte and numerous other industry thought leaders who have reached out to us to learn more about PharmaCyte.”

    BIO is the world’s largest biotechnology convention. It attracts over 16,000 biotechnology and pharma leaders who come together for one week of intensive networking to discover new opportunities and promising partnerships. BIO brings together a wide spectrum of life science and application areas, including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy. There will be more than 40,000 BIO “One-on-One Partnering” meetings, approximately 1,800 exhibitors (including 50 State and International pavilions), 150 educational sessions and 300 company presentations – a record breaking number for BIO.

    About PharmaCyte Biotech

    PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

    PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through the encapsulated cells, they act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no treatment related side effects.

    PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.

    Safe Harbor

    This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

    More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.

    Investor Relations:
    PharmaCyte Biotech, Inc.
    Investor Relations Department
    Telephone: 917.595.2856
    Email: Info@PharmaCyte.com